Since 2015 we have been proud to partner and support clients who are at the forefront of creating groundbreaking new treatments and therapies.
We carefully select and recruit the highest calibre of personnel. Every member of
our team is an expert in their field and passionate about access for Rare Diseases.
As global experts in access for orphan drug, cell and gene therapy,
we truly understand the complexity and challenges of the market
access environment. P4A solutions are designed to be bespoke
to your situation, location and needs. One size does not fit all.
Our 2-minute promotional video will give you a thorough overview
into P4A and our tailored, meticulous and innovative approach.
We are an award-winning global consultancy and recognised
for excellence in access for orphan drugs & Cell and Gene Therapies.
[London, UK] Partners4Access (P4A) is proud to announce the launch of its new Digital Solutions, designed to revolutionize how pharmaceutical companies approach product launches in the rare
Written by Beth McCormick, Senior Analyst France’s cost-effectiveness body, CEESP, currently reviews manufacturer’s economic analyses and determines the potential budget impact on health insurance expenditure.
London, UK – Partners4Access (P4A) is excited to announce that Managing Partner Sophie Schmitz will be attending the highly anticipated Cell & Gene Meeting on
